Orphan Drug Development, LAL Deficiency, Synageva BioPharma Company | |
Synageva was formed to concentrate on orphan drug treatments for rare diseases. Our lead program, SBC-102, is an enzyme replacement therapy for LAL Deficiency | |
Keywords : Lysosomal Acid Lipase (LAL) Deficiency |
Last Update : | 03/January/2012 |
Google PR : | N/A |
Internal links : | 24 |
External links : | 33 |
Archive : | Check how did the site look in the past? |